Becker's Healthcare November 20, 2024
Mackenzie Bean

The FDA granted accelerated approved to the first gene therapy directly administered into the brain on Nov. 14.

The therapy, Kebilidi, was approved to treat adults and children with aromatic L-amino acid decarboxylase deficiency, a rare genetic disorder that affects the body’s ability to produce neurotransmitters that support motor function.

Kebilidi is administered via four infusions into a part of the brain...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech, Provider
Christophe Weber, veteran Takeda CEO, to retire next year
FDA warns GLP-1 compounder over safety rules
Metsera, Maze secure combined $415 million in IPOs
Ozempic-Like Drugs May Hold Risks For Surgical Patients, Officials Say
From discovery to delivery: Finding an investment edge in biopharma services

Share This Article